Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation

Molecular Nutrition and Food Research

Volumn 60, Issue 3, 2016, Pages 519-529

  Terzuoli, Erika ^a   Giachetti, Antonio ^a   Ziche, Marina ^a,b   Donnini, Sandra ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Colon cancer; EGFR degradation; Hydroxytyrosol; Olive oil; Polyphenols

Indexed keywords

3,4-DIHYDROXYPHENYLETHANOL; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; OLIVE OIL; PHENETHYL ALCOHOL; PROTEASOME; TYROSINE;

ANALOGS AND DERIVATIVES; ANIMAL; CACO-2 CELL LINE; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; HT-29 CELL LINE; HUMAN; LYSOSOME; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CACO-2 CELLS; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; LYSOSOMES; MICE, NUDE; OLIVE OIL; PHENYLETHYL ALCOHOL; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959499432     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500498     Document Type: Article

References (46)

1. Hashim, Y. -Z., Eng, M., Gill, C.-I., McGlynn, H. et al., Components of olive oil and chemoprevention of colorectal cancer. Nutr. Rev. 2005, 63, 374-386.
2. Llor, X., Pons, E., Roca, A., Alvarez, M. et al., The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin. Nutr. 2003, 22, 71-79.
3. Bartolí, R., Fernández-Bañares, F., Navarro, E., Castellà, E. et al., Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E(2) synthesis. Gut 2000, 46, 191-199.
4. Owen, R. W., Haubner, R., Würtele, G., Hull, E. et al., Olives and olive oil in cancer prevention. Eur. J. Cancer Prev. 2004, 13, 319-326.
5. Ill, C.-I., Boyd, A., McDermott, E., McCann, M. et al., Potential anti-cancer effects of virgin olive oil phenols on colorectal carcinogenesis models in vitro. Int. J. Cancer 2005, 117, 1-7.
6. Hashim, Y.-Z., Worthington, J., Allsopp, P., Ternan, N.-G. et al., Virgin olive oil phenolics extract inhibit invasion of HT115 human colon cancer cells in vitro and in vivo. Food Funct. 2014, 5, 1513-1519.
7. Hashim, Y.-Z., Rowland, I.-R., McGlynn, H., Servili, M. et al., Inhibitory effects of olive oil phenolics on invasion in human colon adenocarcinoma cells in vitro. Int. J. Cancer 2008, 122, 495-500.
8. Incani, A., Deiana, M., Corona, G., Vafeiadou, K. et al., Involvement of ERK, Akt and JNK signalling in H2O2-induced cell injury and protection by hydroxytyrosol and its metabolite homovanillic alcohol. Mol. Nutr. Food Res. 2010, 54, 788-796.
9. Corona, G., Tzounis, X., Assunta Dessì, M., Deiana, M. et al., The fate of olive oil polyphenols in the gastrointestinal tract: implications of gastric and colonic microflora-dependent biotransformation. Free Radic. Res. 2006, 40, 647-658.
10. Casaburi, I., Puoci, F., Chimento, A., Sirianni, R. et al., Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies. Mol. Nutr. Food Res. 2013, 57, 71-83.
11. Fabiani, R., Rosignoli, P., De Bartolomeo, A., Fuccelli, R. et al., Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21(WAF1/Cip1) and p27(Kip1) and with induction of differentiation in HL60 cells. J. Nutr. 2008, 138, 42-48.
12. Menendez, J.-A., Vazquez-Martin, A., Colomer, R., Brunet, J. et al., Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells. BMC Cancer 2007, 7, 80-99.
13. Fabiani, R., De Bartolomeo, A., Rosignoli, P., Servili, M. et al., Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur. J. Cancer Prev. 2002, 11, 351-358.
14. D'Angelo, S., Ingrosso, D., Migliardi, V., Sorrentino, A. et al., Hydroxytyrosol, a natural antioxidant from olive oil, prevents protein damage induced by long-wave ultraviolet radiation in melanoma cells. Free Radic. Biol. Med. 2005. 38, 908-919.
15. Corona, G., Deiana, M., Incani, A., Vauzour, D. et al., Hydroxytyrosol inhibits the proliferation of human colon adenocarcinoma cells through inhibition of ERK1/2 and cyclin D1. Mol. Nutr. Food Res. 2009, 53, 897-903.
16. Guichard, C., Pedruzzi, E., Fay, M., Marie, J.-C. et al., Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Carcinogenesis 2006, 27, 1812-1827.
17. Terzuoli, E., Donnini, S., Giachetti, A., Iñiguez, M.-A. et al., Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin. Cancer Res. 2010, 16, 4207-4216.
18. Donnini, S., Finetti, F., Solito, R., Terzuoli, E. et al., EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J. 2007, 21, 2418-2430.
19. Donnini, S., Finetti, F., Terzuoli, E., Giachetti, A. et al., EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity. Oncogene 2012, 31, 3457-3466.
20. Finetti, F., Terzuoli, E., Bocci, E., Coletta, I. et al., Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One 2012, 7, e40576.
21. Ciardiello, F., Tortora, G., EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
22. Coffey, R.-J., McCutchen, C.-M., Graves-Deal, R., Polk, W.-H. Jr., Transforming growth factors and related peptides in gastrointestinal neoplasia. J. Cell Biochem. Suppl. 1992, 16G, 111-118.
23. Koretz, K., Schlag, P., Moller, P., Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch. A Pathol. Anat. Histopathol. 1990, 416, 343-349.
24. Yasui, W., Sumiyoshi, H., Hata, J., Kameda, T. et al., Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988, 48, 137-141.
25. Radinsky, R., Risin, S., Fan, D., Dong, Z. et al., Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1995, 1, 19-31.
26. Porebska, I., Harloziska, A., Bojarowski, T., Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000, 21, 105-115.
27. Diaz, L.-A. Jr., Williams, R.-T., Wu, J., Kinde, I. et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486, 537-540.
28. Jonker, D.-J., O'Callaghan C.-J., Karapetis C.-S., Zalcberg, J.-R. et al., Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357, 2040-2048.
29. Galizia, G., Lieto, E., De Vita, F., Orditura, M. et al., Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007, 26, 3654-3660.
30. Cunningham, D., Humblet, Y., Siena, S., Khayat, D. et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
31. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y. et al., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25, 1658-1664.
32. Pai, R., Soreghan, B., Szabo, IL., Pavelka, M. et al., Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002, 8, 289-293.
33. Yamaoka, T., Yan, F., Cao, H., Hobbs, S.-S. et al., Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc. Natl. Acad. Sci. U S A 2008, 105, 11772-11777.
34. Olayioye, M.-A., Neve, R.-M., Lane, H.-A., Hynes, N.-E., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167.
35. Oksvold, M.-P., Thien, C.-B., Widerberg, J., Chantry, A. et al., Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene 2003, 22, 8509-8518.
36. Mosesson, Y., Shtiegman, K., Katz, M., Zwang, Y. et al., Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J. Biol. Chem. 2003, 278, 21323-21326.
37. Beguinot, L., Lyall, R.-M., Willingham, M.-C., Pastan, I., Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc. Natl. Acad. Sci. USA 1984, 81, 2384-2388.
38. Carpenter, G., Cohen, S., Epidermal growth factor. Annu. Rev. Biochem. 1979, 48, 193-216.
39. Levkowitz, G., Waterman, H., Ettenberg, S.-A., Katz, M. et al., Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 1999, 4, 1029-1040.
40. Miro-Casas E., Covas. M. I., Farre, M., Fito, M. et al., Hydroxytyrosol disposition in humans. Clin. Chem. 2003, 49, 945-952.
41. Mateos R., Domínguez M. M., Espartero J. L., Cert A., Antioxidant effect of phenolic compounds, alpha-tocopherol, and other minor components in virgin olive oil. J. Agric. Food Chem. 2003, 51, 7170-7175.
42. Zhang, X., Cao, J., Zhong, L., Hydroxytyrosol inhibits pro-inflammatory cytokines, iNOS, and COX-2 expression in human monocytic cells. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379, 581-586.
43. Salucci S., Burattini S., Battistelli M., Buontempo F. et al., Tyrosol prevents apoptosis in irradiated keratinocytes. J. Dermatol. Sci. 2015, 80, 61-68.
44. Kalaiselvan I., Samuthirapandi M., Govindaraju A., Sheeja Malar D. et al., Olive oil and its phenolic compounds (hydroxytyrosol and tyrosol) ameliorated TCDD-induced heptotoxicity in rats via inhibition of oxidative stress and apoptosis. Pharm. Biol. 2015, 8, 1-9.
45. Padrón, D., Sato, M., Shay, J.-W., Gazdar, A.-F. et al., Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res. 2007, 67, 7695-7702.
46. Kim, H., Frederick, D.-T., Levesque, M.-P., Cooper, Z.-A. et al., Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Rep. 2015, 11, 1458-1473.